🇪🇺 Nevanac in European Union

EMA authorised Nevanac on 11 December 2007

Marketing authorisation

EMA — authorised 11 December 2007

  • Application: EMEA/H/C/000818
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Nevanac
  • Indication: Nevanac is indicated for: prevention and treatment of postoperative pain and inflammation associated with cataract surgery; reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
  • Status: approved

Read official source →

Nevanac in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Pain approved in European Union

Frequently asked questions

Is Nevanac approved in European Union?

Yes. EMA authorised it on 11 December 2007.

Who is the marketing authorisation holder for Nevanac in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.